This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.
Hans-Joachim Schmoll, MD, PhD
Advertisement
Articles by Hans-Joachim Schmoll, MD, PhD
Advertisement
Latest Updated Articles
CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRCJanuary 21st 2017
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
4
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
5